Mantle Cell Lymphoma
Conference Coverage
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Conference Coverage
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
Conference Coverage
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...
Conference Coverage
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
ORLANDO – Orelabrutinib produced an 86% response rate in a phase 2 trial and appears to be safer than ibrutinib.
Opinion
The clinical impact of new approvals in sickle cell, MCL
Dr. Alan P. Lyss puts some recent FDA approval of crizanlizumab and zanubrutinib into perspective for clinicians.
From the Journals
SOX11 shows value as diagnostic marker in MCL
The meta-analysis evaluated the diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma.
From the Journals
Acalabrutinib may outperform other targeted therapies in MCL
The drug showed advantages over targeted monotherapies but was similar to rituximab-based combinations.
News from the FDA/CDC
FDA approves Brukinsa for relapsed, refractory MCL
The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib showed high overall response rates in two clinical trials.
From the Journals
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCL
Investigators reported that the regimen’s efficacy is on par with R-hyperCVAD, but is less toxic.
Feature
ASCO to award $50,000 young investigator grant to study MCL
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
From the Journals
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.